[
    {
        "trialName": "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer",
        "nctNumber": "NCT06058377",
        "status": "RECRUITING",
        "studyType": "INTERVENTIONAL",
        "studyPhases": [
            "PHASE3"
        ],
        "primaryCompletionDate": {
            "date": "2026-05-31",
            "type": "ESTIMATED"
        },
        "completionDate": {
            "date": "2026-05-31",
            "type": "ESTIMATED"
        },
        "startDate": "2023-11-27",
        "startDateType": "ACTUAL",
        "durationDays": 916,
        "daysUntilEnd": 673
    }
]